Form 6-K Zenta Group Co Ltd For: Aug 07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

 

Commission File Number: 001-42826

 

Zenta Group Company Limited

(Registrant’s Name)

 

Avenida do Infante D. Henrique,

No. 47-53A, Macau Square,

13th Floor, Unit M,

Macau 999078

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

“No news” Statement

 

On August 7, 2026, Zenta Group Company Limited, a Cayman Islands exempted company (the “Company”), issued the following statement in response to unusual market action in recent days up to and including August 6, 2026. The Company is announcing that the Company is not aware of any material nonpublic information that have not been publicly disclosed that would account for the recent trading activities.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Zenta Group Company Limited
	By:	/s/ Ng Wai Ian
	Name:	Ng Wai Ian
	Title:	Chief Executive Officer

 

Date: August 7, 2026

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Mackay Gold & Silver Completes Acquisition of Comstock Inc.'s Nevada Mining Assets to Further Consolidate the Comstock District
• Shokz Introduces OpenRun Air 2 and OpenFit Air 2, Expanding Its Bone Conduction and Open-Ear True Wireless Lineups
• Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation